Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review
<p>Immune checkpoint inhibitors (ICIs)—anti-programmed death-1 (PD-1) and their ligands (PD-L1 and PD-L2) have become widely used in the treatment of several malignancies. Many immune-related adverse events (irAEs) have been linked to these agents. Nonetheless, tuberculosis (TB) reactivation d...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513568104251392 |
|---|---|
| author | Aasir M. Suliman (14150217) |
| author2 | Shaza A. Bek (14150220) Mohamed S. Elkhatim (14150223) Ahmed A. Husain (11819156) Ahmad Y. Mismar (14150226) M. Z. Sharaf Eldean (14150229) Zsolt Lengyel (3427871) Shereen Elazzazy (9545774) Kakil I. Rasul (14150232) Nabil E. Omar (9545756) |
| author2_role | author author author author author author author author author |
| author_facet | Aasir M. Suliman (14150217) Shaza A. Bek (14150220) Mohamed S. Elkhatim (14150223) Ahmed A. Husain (11819156) Ahmad Y. Mismar (14150226) M. Z. Sharaf Eldean (14150229) Zsolt Lengyel (3427871) Shereen Elazzazy (9545774) Kakil I. Rasul (14150232) Nabil E. Omar (9545756) |
| author_role | author |
| dc.creator.none.fl_str_mv | Aasir M. Suliman (14150217) Shaza A. Bek (14150220) Mohamed S. Elkhatim (14150223) Ahmed A. Husain (11819156) Ahmad Y. Mismar (14150226) M. Z. Sharaf Eldean (14150229) Zsolt Lengyel (3427871) Shereen Elazzazy (9545774) Kakil I. Rasul (14150232) Nabil E. Omar (9545756) |
| dc.date.none.fl_str_mv | 2022-11-22T21:11:50Z |
| dc.identifier.none.fl_str_mv | 10.1007/s00262-020-02726-1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Tuberculosis_following_programmed_cell_death_receptor-1_PD-1_inhibitor_in_a_patient_with_non-small_cell_lung_cancer_Case_report_and_literature_review/21596955 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Oncology and carcinogenesis Cancer Research Oncology Immunology Immunology and Allergy |
| dc.title.none.fl_str_mv | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>Immune checkpoint inhibitors (ICIs)—anti-programmed death-1 (PD-1) and their ligands (PD-L1 and PD-L2) have become widely used in the treatment of several malignancies. Many immune-related adverse events (irAEs) have been linked to these agents. Nonetheless, tuberculosis (TB) reactivation during their use is increasingly recognized and reported. Herein, we present a 58-year-old lady with advanced non-small cell lung cancer (NSCLC) ALK-negative, EGFR wild, and PD-L1 immune histochemistry (IHC) strongly positive in 95% of tumor cells, on ongoing treatment with Pembrolizumab as a first-line monotherapy. Our patient presented with 1-week history of productive cough and high-grade fever. Further workup yielded the diagnosis of pulmonary tuberculosis after her Pembrolizumab sixth cycle with positive AFB smear and TB PCR from BAL (rifampin resistance not detected), with negative HIV status. Hence, immunotherapy was held, and patient was commenced on anti-TB regimen. History revealed contact with active TB patient over the past decade, without previous documentation of latent TB or previous TB infection. Her sputum AFB smear remained persistently positive 4 weeks through anti-TB regimen course. Later, the patient was discharged after her sputum was cleared from AFB (two negative sets). In light of pembrolizumab mechanism of action as an immune checkpoint inhibitor, we suspected its implication on reactivating latent TB which was observed in our patient demonstrating features of pulmonary tuberculosis. She was not re-challenged with Pembrolizumab following TB diagnosis.</p><h2>Other Information</h2> <p> Published in: Cancer Immunology, Immunotherapy<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s00262-020-02726-1" target="_blank">http://dx.doi.org/10.1007/s00262-020-02726-1</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_55434dfb20fba47a0c77e3d5c00b2e8f |
| identifier_str_mv | 10.1007/s00262-020-02726-1 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21596955 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature reviewAasir M. Suliman (14150217)Shaza A. Bek (14150220)Mohamed S. Elkhatim (14150223)Ahmed A. Husain (11819156)Ahmad Y. Mismar (14150226)M. Z. Sharaf Eldean (14150229)Zsolt Lengyel (3427871)Shereen Elazzazy (9545774)Kakil I. Rasul (14150232)Nabil E. Omar (9545756)Oncology and carcinogenesisCancer ResearchOncologyImmunologyImmunology and Allergy<p>Immune checkpoint inhibitors (ICIs)—anti-programmed death-1 (PD-1) and their ligands (PD-L1 and PD-L2) have become widely used in the treatment of several malignancies. Many immune-related adverse events (irAEs) have been linked to these agents. Nonetheless, tuberculosis (TB) reactivation during their use is increasingly recognized and reported. Herein, we present a 58-year-old lady with advanced non-small cell lung cancer (NSCLC) ALK-negative, EGFR wild, and PD-L1 immune histochemistry (IHC) strongly positive in 95% of tumor cells, on ongoing treatment with Pembrolizumab as a first-line monotherapy. Our patient presented with 1-week history of productive cough and high-grade fever. Further workup yielded the diagnosis of pulmonary tuberculosis after her Pembrolizumab sixth cycle with positive AFB smear and TB PCR from BAL (rifampin resistance not detected), with negative HIV status. Hence, immunotherapy was held, and patient was commenced on anti-TB regimen. History revealed contact with active TB patient over the past decade, without previous documentation of latent TB or previous TB infection. Her sputum AFB smear remained persistently positive 4 weeks through anti-TB regimen course. Later, the patient was discharged after her sputum was cleared from AFB (two negative sets). In light of pembrolizumab mechanism of action as an immune checkpoint inhibitor, we suspected its implication on reactivating latent TB which was observed in our patient demonstrating features of pulmonary tuberculosis. She was not re-challenged with Pembrolizumab following TB diagnosis.</p><h2>Other Information</h2> <p> Published in: Cancer Immunology, Immunotherapy<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s00262-020-02726-1" target="_blank">http://dx.doi.org/10.1007/s00262-020-02726-1</a></p>2022-11-22T21:11:50ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s00262-020-02726-1https://figshare.com/articles/journal_contribution/Tuberculosis_following_programmed_cell_death_receptor-1_PD-1_inhibitor_in_a_patient_with_non-small_cell_lung_cancer_Case_report_and_literature_review/21596955CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215969552022-11-22T21:11:50Z |
| spellingShingle | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review Aasir M. Suliman (14150217) Oncology and carcinogenesis Cancer Research Oncology Immunology Immunology and Allergy |
| status_str | publishedVersion |
| title | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review |
| title_full | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review |
| title_fullStr | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review |
| title_full_unstemmed | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review |
| title_short | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review |
| title_sort | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review |
| topic | Oncology and carcinogenesis Cancer Research Oncology Immunology Immunology and Allergy |